University of Mumbai, Bharati Vidyapeeth's College of Pharmacy, Department of Pharmaceutics, CBD Belapur, Sector-8, Navi-Mumbai-400614, India.
Expert Opin Drug Deliv. 2012 Oct;9(10):1273-88. doi: 10.1517/17425247.2012.716421. Epub 2012 Aug 16.
Aptamers hold great promise as molecular tool in biomedical applications due to the therapeutic utility exhibited by their target specificity and sensitivity. Although current development of aptamer is hindered by its probable in vivo degradation, inefficient immobilization on probe surface, and generation of low detection signal, bioconjugation with nanomaterials can feasibly solve these problems. Nanostructures such as dendrimers, with multivalency and nonimmunogenicity, bioconjugated with aptamers have opened newer vistas for better pharmaceutical applications of aptamers.
This review covers brief overview of aptamers and dendrimers, with specific focus on recent progresses of aptamer-dendrimer (Apt-D) bioconjugate in areas of targeted drug delivery, diagnosis, and molecular imaging along with the discussion on the currently available conjugates, using their in vitro and in vivo results.
The novel Apt-D bioconjugates have led to advances in targeting cancer cell, have amplified biosensing, and offered in vivo cell imaging. Because of the unique properties and applications, Apt-D bioconjugate propose an exciting future. However, further research in synthesis of new target-specific aptamers and their conjugation with dendrimers is required to establish full potential of Apt-D bioconjugate.
由于其靶向特异性和敏感性所表现出的治疗效用，适体作为生物医学应用中的分子工具具有很大的应用前景。尽管当前适体的发展受到其体内可能降解、在探针表面固定效率低以及产生低检测信号等问题的阻碍，但与纳米材料的生物共轭可以有效地解决这些问题。与适体生物共轭的纳米结构，如具有多价性和非免疫原性的树枝状大分子，为更好地将适体应用于药物开辟了新的前景。
本文综述了适体和树枝状大分子的简要概述，特别关注了适体-树枝状大分子（Apt-D）生物偶联物在靶向药物输送、诊断和分子成像领域的最新进展，同时讨论了目前可用的偶联物，包括它们的体外和体内结果。
新型 Apt-D 生物偶联物在靶向癌细胞、放大生物传感和提供体内细胞成像方面取得了进展。由于其独特的性质和应用，Apt-D 生物偶联物提出了令人兴奋的未来。然而，需要进一步研究新的靶向特异性适体的合成及其与树枝状大分子的偶联，以充分发挥 Apt-D 生物偶联物的潜力。
